Work

BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers

Year: 2021

Type: article

Abstract: Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T-cell engager, AMG 160, which binds PSMA and CD3 to induce T-cell–driven cytolytic activity against prostate cancer. See related article by Deegen et al., p. 2928

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-21-0355

Authors: Nikhil V. Kamat, Evan Y. Yu, John K. Lee

Institutions: University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute